Wu Junyu, Tang Guoyi, Cheng Chien-Shan, Yeerken Ranna, Chan Yau-Tuen, Fu Zhiwen, Zheng Yi-Chao, Feng Yibin, Wang Ning
School of Chinese Medicine, the University of Hong Kong, 3, Sasson Road, Pokfulam, Hong Kong.
Department of Digestive Endoscopy Center & Gastroenterology, Shuguang Hospital Affiliated With Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Mol Cancer. 2024 Oct 1;23(1):218. doi: 10.1186/s12943-024-02136-2.
Hepatic, biliary, and pancreatic cancer pose significant challenges in the field of digestive system diseases due to their highly malignant nature. Traditional Chinese medicine (TCM) has gained attention as a potential therapeutic approach with long-standing use in China and well-recognized clinical benefits. In this review, we systematically summarized the clinical applications of TCM that have shown promising results in clinical trials in treating hepatic, biliary, and pancreatic cancer. We highlighted several commonly used TCM therapeutics with validated efficacy through rigorous clinical trials, including Huaier Granule, Huachansu, and Icaritin. The active compounds and their potential targets have been thoroughly elucidated to offer valuable insights into the potential of TCM for anti-cancer drug discovery. We emphasized the importance of further research to bridge the gap between TCM and modern oncology, facilitating the development of evidence-based TCM treatment for these challenging malignancies.
肝癌、胆管癌和胰腺癌因其高度恶性的性质,在消化系统疾病领域构成了重大挑战。中药在中国有着长期的应用历史,其临床益处也得到广泛认可,作为一种潜在的治疗方法受到了关注。在这篇综述中,我们系统地总结了中药在治疗肝癌、胆管癌和胰腺癌的临床试验中显示出有前景结果的临床应用。我们重点介绍了几种经严格临床试验验证有效的常用中药疗法,包括槐耳颗粒、华蟾素和淫羊藿苷。其活性成分及其潜在靶点已得到深入阐明,为中药在抗癌药物研发方面的潜力提供了有价值的见解。我们强调了进一步研究的重要性,以弥合中药与现代肿瘤学之间的差距,促进针对这些具有挑战性的恶性肿瘤的循证中药治疗的发展。